Brief: Foghorn Therapeutics Announces Clinical Data From Phase 1 Study Of FHD-286

Foghorn Therapeutics

28/06/2023 12:41

June 28 (Reuters) - Foghorn Therapeutics Inc.  FHTX.O :
    * FOGHORN THERAPEUTICS INC.: ANNOUNCES CLINICAL DATA FROM
PHASE 1
STUDY OF FHD-286 IN METASTATIC UVEAL MELANOMA
    * FOGHORN THERAPEUTICS INC.: CLINICAL DATA SUPPORT SAFETY
AND
TOLERABILITY PROFILE OF FHD-286
    * FOGHORN THERAPEUTICS INC.: FOGHORN DOES NOT PLAN TO
ADVANCE
FHD-286 IN UVEAL MELANOMA
    * FOGHORN THERAPEUTICS INC.: ANTICIPATES INITIATING A
FHD-286
COMBINATION STUDY IN RELAPSED/REFRACTORY AML DURING Q3 OF 2023

Source text for Eikon:  ID:nGNX1T1qvY 
Further company coverage:  FHTX.O 

 ((reuters.briefs@thomsonreuters.com;))